Virbagen L

Safety and efficacy data are available which demonstrate that this vaccine can be
mixed and administered with vaccines in the Canigen range containing canine
distemper virus, canine adenovirus type 2 , canine parvovirus (strain 154) and/or
canine parainfluenza virus components for subcutaneous administration. The product
information of the relevant Canigen vaccines should be consulted before
administration of the mixed product. When mixed with these Canigen vaccines, the
demonstrated safety and efficacy claims for Canigen Lepto 4 are no different from
those described for Canigen Lepto 4 alone. When mixed with Canigen vaccines
containing canine parainfluenza virus at annual revaccination, it has been
established that there is no interference with the anamnestic response induced by
the injectable canine parainfluenza virus component.
Safety and efficacy data are available which demonstrate that this vaccine can be
administered on the same day but not mixed with vaccines in the Canigen range
containing
intranasal administration.
Safety data are available which demonstrate that this vaccine can be administered at
the same time but not mixed with the inactivated vaccine in the Canigen range
against . When this vaccine is administered in association
with the inactivated vaccine in the Canigen range against Bordetella bronchiseptica
the demonstrated antibody response data and other immunity data of this vaccine
are the same as when this vaccine is administered alone.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the products mentioned above. A
decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case by case basis.